Clinical Trial Update: Effect of Rosiglitazone on Peritoneal Cytokines in Women With Endometriosis [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/Phase 3 trial evaluating rosiglitazone on peritoneal cytokines in women with endometriosis has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometriosis

Drugs mentioned

• Rosiglitazone (rosiglitazone)

Snippet

Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Conditions: Endometriosis | Phase 2, Phase 3 | Status: WITHDRAWN